GlassScriptPhysician profile
Samiullah Khan Kundi
NPI 1932249323
$3,730.43
in general payments reported to CMS, 2019-2025
51 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $265 · 2021: $731 · 2022: $724 · 2023: $719 · 2024: $680 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,570.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $815.53 | 2021-2025 | |
| Abbott Laboratories | $317.66 | 2020-2024 | Proclaim |
| Medtronic, INC. | $265.08 | 2021-2022 | |
| Vertos Medical, INC. | $213.05 | 2022-2023 | Mild Device Kit |
| Azurity Pharmaceuticals, INC. | $161.34 | 2024-2025 | Horizant |
| Medtronic USA, INC. | $138.79 | 2019-2020 | |
| Lilly USA, LLC | $99.80 | 2019-2023 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $96.34 | 2019-2023 | Austedo Xr |
| Pfizer INC. | $93.31 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.46 | 2023 | Relistor |
| Neuronetics, INC. | $89.57 | 2022 | |
| Si-Bone, INC. | $88.11 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $72.16 | 2019 | |
| Zyla Life Sciences, INC. | $68.62 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $66.67 | 2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samiullah Kundi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.